title: Pelvic inflammatory disease. Key treatment issues and options.
abstract: OBJECTIVE
  --To examine available data regarding optimal antimicrobial therapy for pelvic inflammatory disease (PID) and to address selected treatment issues confronting clinicians caring for women with PID.
  
  
  METHODS
  --Studies evaluated to help establish the Centers for Disease Control's 1989 Sexually Transmitted Diseases Treatment Guidelines and other reports published since 1985. A MEDLINE search of English-language literature was conducted using the indexing terms "pelvic inflammatory disease" or "pelvic infections" or "salpingitis" and "treatment". In addition, abstracts and bibliographies of articles and books were reviewed.
  
  
  METHODS
  --Studies were selected for detailed review if they evaluated the effectiveness of an antimicrobial regimen for treatment of PID.
  
  
  METHODS
  --All studies were evaluated to determine the numbers of women treated and the percentage with clinical or microbiologic evidence of cure.
  
  
  RESULTS
  --A variety of combination antimicrobial regimens are highly effective in providing clinical and microbiologic evidence of cure; few data are available to assess optimal therapy for prevention of late sequelae. Because PID is polymicrobial in cause, recommended antimicrobial regimens are broad-spectrum in coverage.
  
  
  CONCLUSIONS
  --No single agent that provides sufficient coverage is currently available. Several combination regimens appear highly effective clinically even among women with tubo-ovarian abscess formation. Uncertainties regarding the effectiveness of antimicrobial therapy for prevention of late sequelae complicate decisions regarding the choice among regimens and the appropriateness of ambulatory treatment of women with PID. Pending better data, hospitalization should be strongly considered, where feasible, particularly for those women with PID desiring further childbearing. Sex partners of all women with PID should be treated.
authors.affiliation: Division of Reproductive Health, Centers for Disease Control, Atlanta, GA 30333.
authors.forename: H B
authors.initials: HB
authors.lastname: Peterson
authors.forename: C K
authors.initials: CK
authors.lastname: Walker
authors.forename: J G
authors.initials: JG
authors.lastname: Kahn
authors.forename: A E
authors.initials: AE
authors.lastname: Washington
authors.forename: D A
authors.initials: DA
authors.lastname: Eschenbach
authors.forename: S
authors.initials: S
authors.lastname: Faro
mesh_terms: D000900:Anti-Bacterial Agents; D002487:Centers for Disease Control and Prevention, U.S.; D002690:Chlamydia Infections / Q000188:drug therapy*; D002692:Chlamydia trachomatis; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy*; D016896:Treatment Outcome; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents